Endologix, Inc. is a developer and manufacturer of minimally invasive treatments for aortic disorders. We have over 850 employees and listed on NASDAQ (ELGX). Since launching in the U.S. in 2005, Endologix has experienced average annual growth of 60%+ and was the top performing med tech stock in 2009. The Company's Powerlink® System is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. More than 2 million people in the U.S. have AAA, with 200,000 new cases diagnosed every year. If left untreated, AAAs become increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the U.S.

Irvine, US
Size (employees)
619 (est)
Endologix is headquartered in Irvine, US

Endologix Office Locations

Endologix has offices in Irvine, Rosmalen
Irvine, US
Rosmalen, NL

Endologix Metrics

Endologix Summary

Market capitalization

$547 M

Closing share price

Endologix's current market capitalization is $547 M.

Endologix Financials

Endologix's revenue is $154 M in FY, 2015 which is a 4.08% increase from the previous period.
FY, 2015FY, 2014FY, 2013


$154 M$148 M$132 M

Revenue growth, %


Gross profit

$102 M$106 M$99.5 M

Operating income

$-52.9 M$-29.1 M$-10.4 M

Operating expense total

$155 M$135 M$110 M

Net Income

$-50.4 M$-32.4 M$-16.1 M

Operating cash flow

$97.8 M$-68.4 M$50 M

Endologix Market Value History

Endologix Company Life